17:39 , Jan 11, 2019 |  BC Week In Review  |  Company News

Genmab's blockbuster Darzalex surpasses $2B in sales

Genmab A/S (CSE:GEN; Pink:GMXAY) said sales of its multiple myeloma drug Darzalex daratumumab reached $2 billion in 2018, triggering a $75 million milestone payment from partner Janssen Biotech Inc. Last February, Genmab projected that 2018...
21:05 , Jan 10, 2019 |  BC Innovations  |  Emerging Company Profile

Kleo: small molecule immuno-oncology

Kleo Pharmaceuticals Inc. is tapping small molecules' advantages over biologics by synthesizing compounds that mimic or modify the functions of antibodies as cancer immunotherapies. The company spun out of Yale University in 2015 with IP...
22:44 , Jan 8, 2019 |  BC Extra  |  Company News

Genmab's blockbuster Darzalex surpasses $2B in sales

Genmab A/S (CSE:GEN; Pink:GMXAY) said sales of its multiple myeloma drug Darzalex daratumumab reached $2 billion in 2018, triggering a $75 million milestone payment from partner Janssen Biotech Inc. Last February, Genmab projected that 2018...
20:59 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Darzalex combo meets PFS endpoint in first-line MM

Genmab A/S (CSE:GEN; Pink:GMXAY) and Janssen Biotech Inc. said Darzalex daratumumab plus Revlimid lenalidomide and dexamethasone met the primary endpoint of improving progression-free survival (PFS) in the Phase III MAIA trial to treat newly diagnosed...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
15:56 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Kleo raises $21M series B to advance to clinic in 2020

Immuno-oncology company Kleo Pharmaceuticals Inc. (New Haven, Conn.) raised $21 million in an untranched series B round on Nov. 13 to propel its next-generation Antibody Recruiting Molecules (ARMs) into the clinic by 2020. The round...
18:00 , Nov 9, 2018 |  BC Week In Review  |  Company News

MorphoSys shares jump amid Tremfya guidance, MOR208 data

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) shares rose Nov. 6 after the company said in its 3Q18 earnings that plaque psoriasis drug Tremfya guselkumab could generate 2018 royalties at the upper end of the biotech's previous guidance....
23:40 , Nov 6, 2018 |  BC Extra  |  Company News

MorphoSys shares jump amid Tremfya guidance, MOR208 data

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) shares rose Tuesday after the company said in its 3Q18 earnings that plaque psoriasis drug Tremfya guselkumab could generate 2018 royalties at the upper end of the biotech's previous guidance. MorphoSys...
17:59 , Oct 19, 2018 |  BC Week In Review  |  Company News

J&J stalls development of antiviral from Alios deal

Johnson & Johnson (NYSE:JNJ) has stalled development of lumicitabine (AL-8176), an antiviral candidate that was a key to its $1.75 billion acquisition of Alios BioPharma Inc. in 2014, and revealed a resulting impairment charge of...
21:43 , Oct 16, 2018 |  BC Extra  |  Company News

J&J stalls development of antiviral from Alios deal

Johnson & Johnson (NYSE:JNJ) has stalled development of lumicitabine (AL-8176), an antiviral candidate that was a key to its $1.75 billion acquisition of Alios BioPharma Inc. in 2014, and revealed a resulting impairment charge of...